The Flowr Corporation (TSXV:FLWR) CEO Vinay Tolia was recently featured in an interview with James West, from Midas Letter Live. In the interview, Tolia discussed how his company, which was co-founded by MedReleaf co-founder Tom Flow, is focused on producing premium quality cannabis for consumers. Tolia said Flowr is using high-tech cultivation facilities and processes developed by Flow to grow high-quality cannabis profitably and at scale. These systems also let the company grow without the use of irradiation, which can often have an impact on taste and smell.

The Flowr Corporation will have products for both the recreational and the medical markets, all grown in its 85,000-square-foot indoor grow facility in Kelowna. “It’s about 20 percent operational right now; it’ll be fully operational in the next four to five months, and, you know, we’re very excited about that. Once that’s done, we have plans for a larger facility next door that could be potentially five times the size,” said Tolia.

The facility may be the most advanced growing facility in Canada as the Flowr team has continually evolved designs and systems for the many cultivation facilities they have built. Tolia claims that the company’s construction and design team is their core strength, and they brought their experience in design, engineering and cultivation for the development of their facility. As the global market continues to expand, Tolia believes that the company will look into replicating this type of facility across multiple jurisdictions in the world.

To wrap up the interview, Tolia also discussed the company’s commercial and R&D partnerships with Ace Hill Beer and Scotts Miracle-Gro (NYSE:SMG), respectively. The partnership with Scotts makes The Flowr Corporation one of only three cannabis companies to have a relationship with a NYSE-listed company. Tolia also mentioned the company’s interest in hemp-derived CBD and potential partnerships with pharmaceutical and wellness companies in that market.

To watch the full interview, click here.

Click here to connect with The Flowr Corporation (TSXV:FLWR) for an Investor Presentation

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info:

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less